Sort
8,912 grants matching “sars cov 2”
Zotatifin treatment of adults with mild to moderate COVID-19
$87,364Harry L Malech · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Clinical and Translational Science Award
$87,330Reza Shaker · Medical College Of Wisconsin · UL1 · FY2022 · TR
Actions of Restriction Factors on Coronaviruses
$87,268Alan Rein · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Structural and Functional Analysis of the Coronavirus Spike Protein Fusion Peptide
$87,264Gary R Whittaker · Cornell University · R01 · FY2020 · AI
Translational Nanobiology Approaches to Viral Diseases (HIV, HTLV, SARS-CoV2)
$86,642Jennifer Jones · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Communication and Coping: Addressing Mothers' Needs to Improve Outcomes in Adolescents with T1D
$86,488Sarah Sanders Jaser · Vanderbilt University Medical Center · R01 · FY2021 · DK
MLL1 drives collaborative leukocyte-endothelial cell signaling and thrombosis after coronavirus infection
$86,392Nathaniel Parchment · University Of Michigan At Ann Arbor · F32 · FY2024 · HL
HWWTP
$86,307David Turcotte · University Of Massachusetts Lowell · U45 · FY2020 · ES
The Impact of SARS-CoV-2 Infection and Vaccination on the Risk of Alzheimerâs Disease and Related Dementias
$86,020Jingxuan Wang · Harvard University D/B/A Harvard School Of Public Health · K00 · FY2025 · AG
ECMO without Anticoagulation
$85,938Alvaro Rojas-Pena · University Of Michigan At Ann Arbor · R01 · FY2023 · HL
SARS CoV2 Studies in the Microbial Pathogenesis Section/LPD
$85,822Stephen Leppla · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Translational Nanobiology Approaches to Viral Diseases (HIV, HTLV, SARS-CoV2)
$85,728Jennifer Jones · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Incidence, Outcomes, and Predictors of Sepsis in Hospitalized Patients with COVID-19
$85,610Claire Shappell · Brigham And Women'S Hospital · F32 · FY2022 · GM
Transitions Among Discrete Clinical States During ICU Stays in Patients with SARS-CoV-2 Pneumonia
$85,550Catherine A. Gao · Northwestern University At Chicago · F32 · FY2022 · HL
COVID-19: 3D Bioprinted Tissue Models for Respiratory Viruses
$85,450Marc Ferrer · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR
The Interaction of Public Health Emergencies: Understanding Nation-wide and City-wide Spatiotemporal Dynamics of COVID-19 Transmission in a Warming World
$84,750Arnab Kumar Ghosh · Weill Medical Coll Of Cornell Univ · R03 · FY2024 · TR
The Interaction of Public Health Emergencies: Understanding Nation-wide and City-wide Spatiotemporal Dynamics of COVID-19 Transmission in a Warming World
$84,750Arnab Kumar Ghosh · Weill Medical Coll Of Cornell Univ · R03 · FY2025 · TR
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$84,698Alfred Ayala · Rhode Island Hospital · R35 · FY2023 · GM
Modular synthesis of antibiotic and anticancer classes of natural products
$84,553Ian Bass Seiple · University Of California, San Francisco · R35 · FY2024 · GM
Conference: USA-UK-China-Israel Workshop on Frontiers in Ecology and Evolution of Infectious Diseases
$84,260Xiangming Xiao · University Of Oklahoma Norman Campus · · FY2024 · BIO
Manipulating nucleic acids: applications in RNA biosensing, single-molecule analysis, and DNA nanotechnology
$84,134Ken A Halvorsen · State University Of New York At Albany · R35 · FY2024 · GM
COVID-19 Serosurveys and Vaccine Study Site Preparations
$84,110Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Building testing capacity for past and current SARS-CoV-2 infection in animals with potential exposure to humans with COVID-19
$83,739Ailam Lee Lim · University Of Wisconsin-Madison · U18 · FY2021 · FD
COVID-19: Viral whole genome sequencing protocols for routine application at veterinary diagnostic laboratories
$83,734Albert Rovira · University Of Minnesota · U18 · FY2023 · FD
ECMO without Anticoagulation
$83,643Alvaro Rojas-Pena · University Of Michigan At Ann Arbor · R01 · FY2024 · HL